Overview
- Tuesday's full results from two international Phase 3 trials showed tozorakimab reduced moderate‑to‑severe COPD exacerbations by about 29% to 34% versus placebo over roughly one year.
- The benefit was seen across a wide group of patients regardless of smoking status, lung‑function severity, or blood eosinophil levels, including people not eligible for existing COPD biologics.
- Overall adverse events and serious adverse events were similar to placebo in the trials, with injection‑site reactions the main tolerability signal reported by investigators.
- The FDA has accepted the application for priority review and set a PDUFA target in Q1 2027 while AstraZeneca has raised its peak sales forecast above $5 billion and is pursuing reviews in other major markets.
- Key open questions include the absence of head‑to‑head trials versus approved COPD biologics, requested subgroup and comparative analyses, and upcoming guideline decisions that will shape which patients receive the drug and how widely it is used.